Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences, a developer of commercial applications derived from its proprietary Mimetic Ligand technology, has received additional $4m purchase order for Mimetic Ligand affinity adsorbent, under an agreement with a pharma firm which was originally signed in 2009.
Subscribe to our email newsletter
Developed by ProMetic’s subsidiary ProMetic Biosciences, Mimetic Ligand affinity adsorbent is expected to be supplied in the third and fourth quarters of 2011.
Further, the supply agreement allows ProMetic to supply a purification component to the client in the event of any manufacturing scale-up of the biopharmaceutical product in anticipation of regulatory approval and market launch.
ProMetic president and CEO Pierre Laurin said repeat orders from client underscore the company’s ability to consistently meet its clients’ large scale present and future manufacturing process needs.